Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.

Studies into the genetic origins of tumor cell chemoactivity pose significant challenges to bioinformatic mining efforts. Connections between measures of gene expression and chemoactivity have the potential to identify clinical biomarkers of compound response, cellular pathways important to efficacy...

Full description

Bibliographic Details
Main Author: David G Covell
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3462800?pdf=render
id doaj-41dbce99ed954bebbd59a0a5a9599457
record_format Article
spelling doaj-41dbce99ed954bebbd59a0a5a95994572020-11-25T01:14:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01710e4463110.1371/journal.pone.0044631Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.David G CovellStudies into the genetic origins of tumor cell chemoactivity pose significant challenges to bioinformatic mining efforts. Connections between measures of gene expression and chemoactivity have the potential to identify clinical biomarkers of compound response, cellular pathways important to efficacy and potential toxicities; all vital to anticancer drug development. An investigation has been conducted that jointly explores tumor-cell constitutive NCI60 gene expression profiles and small-molecule NCI60 growth inhibition chemoactivity profiles, viewed from novel applications of self-organizing maps (SOMs) and pathway-centric analyses of gene expressions, to identify subsets of over- and under-expressed pathway genes that discriminate chemo-sensitive and chemo-insensitive tumor cell types. Linear Discriminant Analysis (LDA) is used to quantify the accuracy of discriminating genes to predict tumor cell chemoactivity. LDA results find 15% higher prediction accuracies, using ∼30% fewer genes, for pathway-derived discriminating genes when compared to genes derived using conventional gene expression-chemoactivity correlations. The proposed pathway-centric data mining procedure was used to derive discriminating genes for ten well-known compounds. Discriminating genes were further evaluated using gene set enrichment analysis (GSEA) to reveal a cellular genetic landscape, comprised of small numbers of key over and under expressed on- and off-target pathway genes, as important for a compound's tumor cell chemoactivity. Literature-based validations are provided as support for chemo-important pathways derived from this procedure. Qualitatively similar results are found when using gene expression measurements derived from different microarray platforms. The data used in this analysis is available at http://pubchem.ncbi.nlm.nih.gov/andhttp://www.ncbi.nlm.nih.gov/projects/geo (GPL96, GSE32474).http://europepmc.org/articles/PMC3462800?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author David G Covell
spellingShingle David G Covell
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
PLoS ONE
author_facet David G Covell
author_sort David G Covell
title Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
title_short Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
title_full Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
title_fullStr Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
title_full_unstemmed Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
title_sort integrating constitutive gene expression and chemoactivity: mining the nci60 anticancer screen.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Studies into the genetic origins of tumor cell chemoactivity pose significant challenges to bioinformatic mining efforts. Connections between measures of gene expression and chemoactivity have the potential to identify clinical biomarkers of compound response, cellular pathways important to efficacy and potential toxicities; all vital to anticancer drug development. An investigation has been conducted that jointly explores tumor-cell constitutive NCI60 gene expression profiles and small-molecule NCI60 growth inhibition chemoactivity profiles, viewed from novel applications of self-organizing maps (SOMs) and pathway-centric analyses of gene expressions, to identify subsets of over- and under-expressed pathway genes that discriminate chemo-sensitive and chemo-insensitive tumor cell types. Linear Discriminant Analysis (LDA) is used to quantify the accuracy of discriminating genes to predict tumor cell chemoactivity. LDA results find 15% higher prediction accuracies, using ∼30% fewer genes, for pathway-derived discriminating genes when compared to genes derived using conventional gene expression-chemoactivity correlations. The proposed pathway-centric data mining procedure was used to derive discriminating genes for ten well-known compounds. Discriminating genes were further evaluated using gene set enrichment analysis (GSEA) to reveal a cellular genetic landscape, comprised of small numbers of key over and under expressed on- and off-target pathway genes, as important for a compound's tumor cell chemoactivity. Literature-based validations are provided as support for chemo-important pathways derived from this procedure. Qualitatively similar results are found when using gene expression measurements derived from different microarray platforms. The data used in this analysis is available at http://pubchem.ncbi.nlm.nih.gov/andhttp://www.ncbi.nlm.nih.gov/projects/geo (GPL96, GSE32474).
url http://europepmc.org/articles/PMC3462800?pdf=render
work_keys_str_mv AT davidgcovell integratingconstitutivegeneexpressionandchemoactivityminingthenci60anticancerscreen
_version_ 1725158726552256512